


How similar is this cluster to the other clusters?




Genes in the cluster along with the pathways as annotated by experts

Treatment	Expert Annotation	
	Pathway	Regulation Type
SMAD3.WT.1	Canonical SMAD	Activator
RBPJ.WT.1	NOTCH	Activator
RBPJ.WT.2	NOTCH	Activator


Top 5 genes negatively correlated to the cluster

Treatment	Expert Annotation		Mean Correlation	Standard Deviation
	Pathway	Regulation Type		
RAFI.WT.2	Canonical MAPK	Activator	-0.62	0.06
CXCC4.WT	WNT	Inhibitor	-0.60	0.01
STK3.WT.1	Canonical Hippo	Activator	-0.60	0.09
MAP3K2.WT.1	Canonical MAPK	Activator	-0.58	0.16
PIK3CB.WT.2	Canonical PI3K/AKT	Activator	-0.55	0.13

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?




Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)

Empty





RBPJ_WT.1




RBPJ_WT.2

SMAD3_WT.1


ER

RNA

<div>Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster</div>	<div>Chemical structure</div>	<div>Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.54)</div>	<div>Mean \pm standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes</div> <div>Mean compound rank when scored against genes in cluster using L1000 profiling \pm standard deviation; Tables contain data for individual genes</div>	<div>How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)</div>	<div>Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples</div>	<div>Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster</div>	<div>Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized</div>											
<div>BRD-K04968712-001-05-7 MLS000858711 SMR000458790 AC1MDPY6 BDBM45738 HMS2811A04 ZINC1034543 ZINC01034543 PubChem CID : 2814981</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div>0.58 \pm 0.06</div> <table><thead><tr><th>Treatment</th><th>Score</th></tr></thead><tbody><tr><td>BRD-K04968712-001-05-7</td><td>0.60</td></tr><tr><td>BRD-K04968712-001-05-7</td><td>0.61</td></tr><tr><td>BRD-K04968712-001-05-7</td><td>0.62</td></tr><tr><td>BRD-K04968712-001-05-7</td><td>0.63</td></tr></tbody></table>	Treatment	Score	BRD-K04968712-001-05-7	0.60	BRD-K04968712-001-05-7	0.61	BRD-K04968712-001-05-7	0.62	BRD-K04968712-001-05-7	0.63	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 545. Active in the following assays:</div> <div><ul style="list-style-type: none">Factor XIIa 1536 HTS (AID 800)Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504832)Primary qHTS for delayed death inhibitors of the malarial parasite plasid, 96 hour incubation (AID 504834)Confirmation screen for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504848)Confirmation screen for delayed death inhibitors of the malarial parasite plasid, 48 hour incubation (AID 504850)qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line (AID 686971)</div>
Treatment	Score																	
BRD-K04968712-001-05-7	0.60																	
BRD-K04968712-001-05-7	0.61																	
BRD-K04968712-001-05-7	0.62																	
BRD-K04968712-001-05-7	0.63																	

BRD-K52184420-001-01-4 PubChem CID : 54645920		NA (in 1 replicates)	<div><div>0.56 ± 0.09</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>0.56</td></tr><tr><td>RBP3.WT.2</td><td>0.46</td></tr><tr><td>SMAD3.WT.1</td><td>0.65</td></tr></table></div> <div><div>0.148 ± 0.102</div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>0.081</td></tr><tr><td>RBP3.WT.2</td><td>0.218</td></tr><tr><td>SMAD3.WT.1</td><td>0.106</td></tr></table></div>	Treatment	Score	RBP3.WT.1	0.56	RBP3.WT.2	0.46	SMAD3.WT.1	0.65	Treatment	Score	RBP3.WT.1	0.081	RBP3.WT.2	0.218	SMAD3.WT.1	0.106			<div><div>Cytoplasm_Intensity_MaxIntensityEdge_AGP</div><div>Cytoplasm_Intensity_MaxIntensity_Mito</div><div>Cells_RadialDistribution_RadialCV_ER_1044</div><div>Cells_RadialDistribution_RadialCV_AGP_3044</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div>Cells_Intensity_IntegratedIntensityEdge_AGP</div><div>Cells_Intensity_IntegratedIntensityEdge_ER</div><div></div></div>
Treatment	Score																					
RBP3.WT.1	0.56																					
RBP3.WT.2	0.46																					
SMAD3.WT.1	0.65																					
Treatment	Score																					
RBP3.WT.1	0.081																					
RBP3.WT.2	0.218																					
SMAD3.WT.1	0.106																					




BRD-K85382133-001-05-4
ASN 03792177
SMR000002532
AC1NU7DR
MLS000073949
MLS001385610
HMS2395N21
PubChem CID : 5447101



NA (in 1 replicates)

Treatment	Score
RBPJ.WT.1	0.50
RBPJ.WT.2	0.41
SMAD3.WT.1	0.54


NA



Total number of assays tested in: 768. Active in the following assays:

- Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen (AID 628)
- Primary biochemical high throughput screening assay to identify inhibitors of VIM-5 metallo-beta-lactamase (AID 1527)
- HTS absorbance assay for the identification of compounds that inhibit PHOSPHO (AID 1565)
- Cytochrome panel assay with activity outcomes (AID 1851)
- HTS-Luminescent assay for inhibitors of ALP by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02 Inhibitor SinglePoint HTS (AID 485317)
- Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 48 hour incubation (AID 504832)
- Counter-screen of compound fluorescence of a high-throughput multiplexed microsphere screening for inhibitors of toxin proteases (AID 621483)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)
- qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)



BRD-A83852736-001-06-9
T5235042
SMR000063406
AC1MHBUZ
MLS000053977
MLS002635527
TCMDC-143594
HMS1727O03
HMS2385I15
PubChem CID : 2999476



0.66 (in 2 replicates)

Treatment	Score
RBPJ.WT.1	-0.49
RBPJ.WT.2	-0.52
SMAD3.WT.1	-0.49


NA



Total number of assays tested in: 805. Active in the following assays:

- Screening for Modulators of Post-Golgi Transport, Control Strain (AID 738)
- gHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase) (AID 894)
- Leishmania major promastigote HTS (AID 1063)
- Leishmania major promastigote HTS - primary screen report 1 uM (AID 1258)
- CounterScreen for inhibitors of Janus kinase 2 mutant JAK2^{G167F}: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability. (AID 1486)
- Leishmania Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruz Replication (AID 1885)
- Leishmania major promastigote EC50 determinations (AID 2008)
- Luminescence Cell-Based/Microorganism Dose Confirmation HTS to Identify Inhibitors of T.Cruz Replication. (AID 2044)
- Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the nociceptin 1 receptor (OX1R; HCRTR1) (AID 43089)
- gHTS profiling assay for firefly luciferase in inhibitor/activator using purified enzyme and Km concentrations of substrates (counterScreen for miR-21 project) (AID 58342)
- Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A) (AID 58851)
- uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 60249)
- gHTS for Antagonists of gsp, the Ethanol-galactose Mutation Responsible for Fibrosis (Asplasia/McCune-Albright Syndrome; gHTS (AID 62488)
- Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) (AID 62466)
- Single concentration confirmation of uHTS in inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 62450)
- Trypanosoma brucei. Primary growth inhibition assay (AID 1159557)
- TeCPY61 enzymatic inhibition (AID 1159558)
- Trypanosoma cruzi. Primary growth inhibition assay (AID 1159559)
- Leishmania donovani. Primary growth inhibition assay (AID 1159560)
- Intra-macrophage L. donovani assay (AID 1159564)
- Trypanosoma cruzi intracellular imaging assay (AID 1159565)




BRD-K21786986-001-05-1
MLS001163353
SMR000497279
ZINC00306713
AC1LFCBC9
Ambcb6914459
BDBM76621
HMS2823C13
ZINC306713
STL420213
PubChem CID : 800252



0.68 (in 4 replicates)

















Treatment	Score
RBPJ.WT.1	-0.56
RBPJ.WT.2	-0.46
SMAD3.WT.1	-0.45


0.271 ± 0.042	
Treatment	Score
RBPJ.WT.1	0.270
RBPJ.WT.2	0.230
SMAD3.WT.1	0.314



Total number of assays tested in: 504. Active in the following assays:

- MLLPCN Alpha-Synuclein 5'UTR - 3'UTR Inhibitor - activators (AID 1814)
- Cycloheximide CounterScreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
- a hTfTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
- hTfTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENPS8) (AID 2540)
- hTfTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENPS6) (AID 2509)
- A yeast HfTS for caloric restriction mimetics that inhibit age-related superoxide (AID 2690)
- Dose Response confirmation of inhibitors of Sentrin-specific proteases (SENPS) using a Caspase-3 Selectivity assay (AID 488901)
- Dose Response confirmation of hTfTS for inhibitors of Sentrin-specific protease 8 (SENPS8) using a Luminescent assay (AID 488903)
- Dose Response confirmation of hTfTS for inhibitors of Sentrin-specific protease 7 (SENPS7) using a Luminescent assay (AID 488904)
- Single concentration confirmation of hTfTS for inhibitors of Sentrin-specific protease 7 (SENPS7) using a Luminescent assay (AID 488917)
- Dose Response confirmation of hTfTS for inhibitors of Sentrin-specific protease 6 (SENPS6) using a Luminescent assay (AID 488921)
- SAR Analysis of small molecule inhibitors of Sentrin-specific proteases (SENPS) using a Caspase-3 Selectivity assay (AID 504488)
- SAR Analysis of small molecule inhibitors of Sentrin-specific protease 6 (SENPS6) using a Luminescent assay (AID 504492)
- SAR Analysis of small molecule inhibitors of Sentrin-specific protease 7 (SENPS7) using a Luminescent assay (AID 504497)
- SAR Analysis of small molecule inhibitors of Sentrin-specific protease 8 (SENPS8) using a Luminescent assay (AID 504501)
- MTTF Measured in Cell-Based System Using Plate Reader - 208401.01. Activator. Dose. CherryPick Activity (AID 504208)
- MTTF Act. Counter Assay: HeLa CytG Assay Measured in Cell-Based System Using Plate Reader - 208401.01. Activator. Dose. CherryPick Activity (AID 504209)
- qHTS profiling assay for firefly luciferase in inhibitor/activator using purified enzyme and Kinase concentrations of substrates (counterscreen for mR-21) (AID 588342)
- qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression (AID 624202)
- MTTF Measured in Cell-Based System Using Plate Reader - 208401.01. Activator. Dose. DryPowder. Activity (AID 651775)

<div>BRD-K43089177-001-06-1</div> <div>SMR000123694</div> <div>MLS000123058</div> <div>STK178377</div> <div>AC1LL2IR</div> <div>BDBM73383</div> <div>HMS1914K05</div> <div>HMS2437P20</div> <div>ZINC789542</div> <div>ZINC00789542</div> <div>BAS 05018824</div> <div>ST50276881</div> <div>K786-1645</div> <div>PubChem CID : 1077699</div>		NA (in 1 replicates)	<div>-0.48 ± 0.09</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>-0.48</td></tr><tr><td>BBP3.WT.2</td><td>-0.40</td></tr><tr><td>SMAD3.WT.1</td><td>-0.40</td></tr></table>	Treatment	Score	BBP3.WT.1	-0.48	BBP3.WT.2	-0.40	SMAD3.WT.1	-0.40	NA				<div>Total number of assays tested in: 700. Active in the following assays:</div> <ul style="list-style-type: none">Leishmania major promastigote HTS (AID 1063)Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells (AID 1296)Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen (AID 1456)Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Retesting of RCC2 cells with Ouabain (AID 1717)Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methyltransferase 1 (PME-1). (AID 2130)Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of Protein Phosphatase Methyltransferase 1 (PME-1). (AID 2171)Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction (AID 2629)uHTS fluorescent assay for identification of inhibitors of ATG4B (AID 504462)Dose response confirmation of the uHTS fluorescent assay for identification of inhibitors of ATG4B. (AID 504756)Single concentration confirmation of inhibitors of ATG4B via a fluorescent assay (AID 504757)Primary qHTS for delayed death inhibitors of the malarial parasite plasmod, 96 hour incubation (AID 504834)Dose response counterscreen of uHTS hits for ATG4B inhibitors in a Phospholipase A2 assay (AID 588400)								
Treatment	Score																							
BBP3.WT.1	-0.48																							
BBP3.WT.2	-0.40																							
SMAD3.WT.1	-0.40																							
<div>BRD-K69565703-001-02-1</div> <div>MLS003129137</div> <div>SMR00183583</div> <div>PubChem CID : 44505995</div>		0.69 (in 2 replicates)	<div>-0.47 ± 0.02</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>-0.40</td></tr><tr><td>BBP3.WT.2</td><td>-0.47</td></tr><tr><td>SMAD3.WT.1</td><td>-0.45</td></tr></table>	Treatment	Score	BBP3.WT.1	-0.40	BBP3.WT.2	-0.47	SMAD3.WT.1	-0.45	<div>0.434 ± 0.418</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>0.899</td></tr><tr><td>BBP3.WT.2</td><td>0.000</td></tr><tr><td>SMAD3.WT.1</td><td>0.334</td></tr></table>	Treatment	Score	BBP3.WT.1	0.899	BBP3.WT.2	0.000	SMAD3.WT.1	0.334				<div>Total number of assays tested in: 227.</div>
Treatment	Score																							
BBP3.WT.1	-0.40																							
BBP3.WT.2	-0.47																							
SMAD3.WT.1	-0.45																							
Treatment	Score																							
BBP3.WT.1	0.899																							
BBP3.WT.2	0.000																							
SMAD3.WT.1	0.334																							
<div>BRD-K86946907-001-01-8</div> <div>PubChem CID : 44494582</div>		0.64 (in 4 replicates)	<div>-0.46 ± 0.04</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>-0.48</td></tr><tr><td>BBP3.WT.2</td><td>-0.42</td></tr><tr><td>SMAD3.WT.1</td><td>-0.39</td></tr></table>	Treatment	Score	BBP3.WT.1	-0.48	BBP3.WT.2	-0.42	SMAD3.WT.1	-0.39	<div>0.711 ± 0.382</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>0.270</td></tr><tr><td>BBP3.WT.2</td><td>0.091</td></tr><tr><td>SMAD3.WT.1</td><td>0.022</td></tr></table>	Treatment	Score	BBP3.WT.1	0.270	BBP3.WT.2	0.091	SMAD3.WT.1	0.022				<div>Total number of assays tested in: 34. Active in the following assays:</div> <ul style="list-style-type: none">MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator:SinglePoint.HTS.Activity (AID 651723)MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator:Dose.CherryPick.Activity-Set6 (AID 720513)
Treatment	Score																							
BBP3.WT.1	-0.48																							
BBP3.WT.2	-0.42																							
SMAD3.WT.1	-0.39																							
Treatment	Score																							
BBP3.WT.1	0.270																							
BBP3.WT.2	0.091																							
SMAD3.WT.1	0.022																							
<div>BRD-K65416179-001-05-9</div> <div>MLS000096952</div> <div>STK127773</div> <div>ZINC01130712</div> <div>AC1LPEM9</div> <div>BDBM33059</div> <div>HMS2275C11</div> <div>ZINC1130712</div> <div>PubChem CID : 1305820</div>		0.57 (in 2 replicates)	<div>-0.46 ± 0.07</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>BBP3.WT.1</td><td>-0.43</td></tr><tr><td>BBP3.WT.2</td><td>-0.42</td></tr><tr><td>SMAD3.WT.1</td><td>-0.34</td></tr></table>	Treatment	Score	BBP3.WT.1	-0.43	BBP3.WT.2	-0.42	SMAD3.WT.1	-0.34	NA				<div>Total number of assays tested in: 749. Active in the following assays:</div> <ul style="list-style-type: none">HIV-1 RT-RNase H MLSCN HTS MH077605 (AID 565)Primary Antimicrobial Assay for E. coli BW25113 and 8710:tolC::kan Protocol for 384-well HTS (AID 573)Antimicrobial Assay for E. coli BW25113 and 8710:tolC::kan - Dose Response (AID 617)HIV-1 RT-RNase H MLSCN HTS MH077605 Confirmation Assay (AID 651)HIV-1 RT-RNase H MLSCN MH077605 Probe Assessment: Dose response Assay (AID 652)CYP2C9 Assay (AID 777)CYP2C19 Assay (AID 778)qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II) (AID 886)qHTS Assay for Inhibitors of 15-LO (15-human lipoxigenase) (AID 887)qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4 (AID 893)qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase) (AID 894)qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) (AID 1030)HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay. (AID 1209)Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen (AID 1362)qHTS Assay for Inhibitors of Bacillus subtilis Slip phosphotransferase (PTase) (AID 1490)HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists (AID 485344)Elicitation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis (AID 488900)A Cell Based Secondary Assay to Explore Compounds that Modulate Non-Replicating, Drug-tolerant Compounds in Replicating H37Rv TB of Mycobacterium tuberculosis (AID 492952)Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2) (AID 492953)uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay (AID 493012)Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2) (AID 493034)Single concentration confirmation of uHTS for APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay (AID 493152)uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay (AID 504690)Inhibitors of the vitamin D receptor (VDR): qHTS (AID 504847)qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: Hit Confirmation (AID 588344)qHTS for Inhibitors of the vitamin D receptor (VDR): Hit Validation in Primary Screen (AID 602199)Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2) (AID 624267)qHTS for Inhibitors of WRN Helicase (AID 651768)qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in absence of CPT (AID 686978)qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDPI): qHTS in cells in presence of CPT (AID 686979)qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)								
Treatment	Score																							
BBP3.WT.1	-0.43																							
BBP3.WT.2	-0.42																							
SMAD3.WT.1	-0.34																							

<div>BRD-A14556598-001-06-7</div> <div>MLS000402296</div> <div>SMR000243030</div> <div>AC1MW1SV</div> <div>AC1Q2RLA</div> <div>BDBM63320</div> <div>CTK6C7395</div> <div>NE61401</div> <div>EN300-05982</div> <div>T0518-2801</div> <div>956370-25-5</div> <div>PubChem CID : 3749969</div>	<div></div>	NA (in 1 replicates)	<div>-0.46 ± 0.05</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>-0.47</td></tr><tr><td>RBP3.WT.2</td><td>-0.41</td></tr><tr><td>SMAD3.WT.1</td><td>-0.49</td></tr></table></div>	Treatment	Score	RBP3.WT.1	-0.47	RBP3.WT.2	-0.41	SMAD3.WT.1	-0.49	NA	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 651. Active in the following assays:</div> <div><ul style="list-style-type: none">Cycloheximide Counter screen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)Confirmatory screen for compounds that activate the Choline Transporter (CHT) (AID 504833)Counter screen assay of the parental HEK293 cells for compounds that activate the Choline Transporter (CHT) (AID 623908)DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01.Other.SinglePoint.HTS.Activity (AID 651640)Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen (AID 652039)Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen (AID 686949)Counter screen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counter screen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence (AID 686952)</div>								
Treatment	Score																							
RBP3.WT.1	-0.47																							
RBP3.WT.2	-0.41																							
SMAD3.WT.1	-0.49																							
<div>BRD-K57969466-001-01-8</div> <div>PubChem CID : 44489309</div>	<div></div>	0.69 (in 4 replicates)	<div>-0.46 ± 0.09</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>-0.40</td></tr><tr><td>RBP3.WT.2</td><td>-0.41</td></tr><tr><td>SMAD3.WT.1</td><td>-0.66</td></tr></table></div> <div>0.429 ± 0.311</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>0.220</td></tr><tr><td>RBP3.WT.2</td><td>0.230</td></tr><tr><td>SMAD3.WT.1</td><td>0.196</td></tr></table></div>	Treatment	Score	RBP3.WT.1	-0.40	RBP3.WT.2	-0.41	SMAD3.WT.1	-0.66	Treatment	Score	RBP3.WT.1	0.220	RBP3.WT.2	0.230	SMAD3.WT.1	0.196		<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 46.</div>
Treatment	Score																							
RBP3.WT.1	-0.40																							
RBP3.WT.2	-0.41																							
SMAD3.WT.1	-0.66																							
Treatment	Score																							
RBP3.WT.1	0.220																							
RBP3.WT.2	0.230																							
SMAD3.WT.1	0.196																							
<div>BRD-A41484464-001-06-0</div> <div>BRN 1211793</div> <div>67086-81-1</div> <div>F1912-0001</div> <div>AC1MCJDX</div> <div>MLSM00678441</div> <div>CTK517353</div> <div>HMS2721O10</div> <div>HE088600</div> <div>KB-92026</div> <div>SMR000323916</div> <div>KB-323361</div> <div>LS-151122</div> <div>PubChem CID : 2771064</div>	<div></div>	NA (in 1 replicates)	<div>-0.45 ± 0.08</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>-0.55</td></tr><tr><td>RBP3.WT.2</td><td>-0.41</td></tr><tr><td>SMAD3.WT.1</td><td>-0.41</td></tr></table></div>	Treatment	Score	RBP3.WT.1	-0.55	RBP3.WT.2	-0.41	SMAD3.WT.1	-0.41	NA	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 617. Active in the following assays:</div> <div><ul style="list-style-type: none">uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay (AID 1012)Aqueous Solubility from MLSMR Stock Solutions (AID 1996)Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1) (AID 652257)</div>								
Treatment	Score																							
RBP3.WT.1	-0.55																							
RBP3.WT.2	-0.41																							
SMAD3.WT.1	-0.41																							
<div>BRD-K71554049-001-05-7</div> <div>SMR000040587</div> <div>MLS000038692</div> <div>MLS002581479</div> <div>AC1LD134</div> <div>HMS2185N19</div> <div>STK373260</div> <div>ZINC17028721</div> <div>ST50908384</div> <div>PubChem CID : 659529</div>	<div></div>	0.58 (in 4 replicates)	<div>-0.45 ± 0.02</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>-0.48</td></tr><tr><td>RBP3.WT.2</td><td>-0.44</td></tr><tr><td>SMAD3.WT.1</td><td>-0.44</td></tr></table></div> <div>0.210 ± 0.144</div> <div><table><tr><th>Treatment</th><th>Score</th></tr><tr><td>RBP3.WT.1</td><td>0.220</td></tr><tr><td>RBP3.WT.2</td><td>0.185</td></tr><tr><td>SMAD3.WT.1</td><td>0.311</td></tr></table></div>	Treatment	Score	RBP3.WT.1	-0.48	RBP3.WT.2	-0.44	SMAD3.WT.1	-0.44	Treatment	Score	RBP3.WT.1	0.220	RBP3.WT.2	0.185	SMAD3.WT.1	0.311		<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 790. Active in the following assays:</div> <div><ul style="list-style-type: none">Human A549 Lung Tumor Cell Growth Inhibition Assay (AID 371)Human H69AR Lung Tumor Cell Growth Inhibition Assay - 86K Screen (AID 598)Modulators of Post-Golgi Transport - 1536-well pilot screen (AID 637)CYP2C9 Assay (AID 777)Primary cell-based high-throughput screening assay to identify antagonists of Galanin Receptor 2 (GALR2) (AID 828)qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway (AID 915)VP16 counter screen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT) (AID 488975)qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a (AID 504332)Nr2 qHTS screen for inhibitors (AID 504444)qHTS for Inhibitors of binding or entry into cells for Lassa Virus (AID 540266)uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex (AID 588475)Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A) (AID 588511)uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449)Single concentration confirmation of uHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504)qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)</div>
Treatment	Score																							
RBP3.WT.1	-0.48																							
RBP3.WT.2	-0.44																							
SMAD3.WT.1	-0.44																							
Treatment	Score																							
RBP3.WT.1	0.220																							
RBP3.WT.2	0.185																							
SMAD3.WT.1	0.311																							